Q-omics provides the consensus-scored BMP10 profile across patient tissues and cancer cell-line models. BMP10 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BMP10 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, BMP10 RNA expression shows 6,306 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where BMP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMP10 survival associations across molecular data types. BMP10 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMP10 RNA expression–survival associations across cancer types. High BMP10 expression shows unfavorable associations in HNSC, COAD and ACC, but favorable associations in PAAD, SCLC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for BMP10 RNA expression.
This table summarizes BMP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BMP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMP10 shows lower tumor expression in LIHC and CHOL and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher BMP10 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p < 0.001).
This table shows molecular features associated with BMP10 in patient tissues and cancer cell lines. In patient samples, BMP10 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, BMP10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
